LONDON / MANILA — November 3, 2026. A bold prediction from one of artificial intelligence’s leading drug-discovery companies is raising the stakes for the global pharmaceutical industry: within five years, AI could become an essential part of developing virtually every new medicine.
Max Jaderberg, president of Alphabet-backed Isomorphic Labs, believes artificial intelligence will fundamentally transform how pharmaceutical companies discover and design treatments.
His vision extends far beyond helping researchers screen potential drug candidates. Isomorphic Labs is developing powerful computer models intended to predict how drug molecules interact with biological targets, allowing scientists to design promising compounds before conducting extensive laboratory experiments.
The company’s ambitions include developing treatments for cancer, immune-related conditions and inflammatory diseases.
But the extraordinary prediction comes with an equally significant challenge.
No AI-designed medicine has yet demonstrated that computer-generated molecular predictions alone can replace the demanding process of human clinical trials and regulatory review.
As pharmaceutical companies race to use AI to accelerate research, scientists are confronting an essential question: Can technology that predicts protein structures and molecular interactions reliably forecast what happens inside a living human body?
Isomorphic Labs President Makes a Bold Five-Year Prediction
Jaderberg’s comments highlight an ambitious future for the pharmaceutical industry.
In a recent interview reported by Business Insider, the Isomorphic Labs president predicted that AI would become a standard part of drug design within five years.
His forecast reflects a belief that advanced computational models will eventually allow scientists to develop medicines more systematically, reducing the costly trial-and-error processes that dominate conventional pharmaceutical research.
However, the prediction should not be interpreted as a confirmed scientific outcome.
It does not mean every medicine will receive regulatory approval through AI.
Nor does it mean human researchers, laboratory experiments and clinical trials will become unnecessary within five years.
Drug design is only one stage in a much larger development process.
The ultimate test remains whether a treatment works safely and effectively in patients.
How Google’s AlphaFold Revolution Helped Launch the Company
Isomorphic Labs was founded in 2021 as a spinout from Google DeepMind, the artificial intelligence research organization behind AlphaFold.
AlphaFold transformed structural biology by enabling researchers to predict three-dimensional protein structures from amino-acid sequences.
Understanding protein structures is essential because proteins perform many biological functions and serve as targets for numerous medicines.
Traditional structural biology often requires expensive and time-consuming experimental techniques.
AI-based predictions can help researchers investigate potential targets more quickly.
The scientific achievement earned Google DeepMind’s Demis Hassabis and John Jumper recognition through the 2024 Nobel Prize in Chemistry, shared with computational protein designer David Baker.
Hassabis subsequently built Isomorphic Labs around the idea that machine learning could do more than predict biological structures.
It could eventually help scientists design entirely new medicines.
But understanding a protein’s shape is not equivalent to knowing whether a medicine will successfully treat a disease.
Drug developers must also evaluate toxicity, dosage, metabolism, unexpected interactions and clinical effectiveness.
Isomorphic’s Drug Design Engine Goes Beyond AlphaFold
In February 2026, Isomorphic Labs unveiled additional details about its proprietary Drug Design Engine, known as IsoDDE.
The company said the system extends beyond protein-structure prediction to address more complicated problems in molecular design.
Its reported capabilities include predicting how strongly candidate medicines bind to their targets and identifying potential binding sites on proteins.
Isomorphic also reported improved performance on selected computational benchmarks compared with AlphaFold 3.
These advances could help scientists identify promising drug candidates and prioritize which molecules deserve further investigation.
That would be commercially significant because laboratory testing is expensive.
An AI system that accurately rejects unsuitable candidates earlier could reduce wasted time and resources.
However, benchmark performance does not establish clinical success.
Some molecules that appear promising in computer simulations fail when tested in cells, animals or human participants.
The company must demonstrate that its technology generates candidates that perform reliably beyond controlled computational assessments.
The $2.1-Billion Investment Behind Isomorphic’s Ambitions
Isomorphic Labs has attracted substantial investor interest.
In May 2026, the company announced a $2.1-billion Series B financing round led by Thrive Capital.
Investors included Alphabet and other major financial and technology backers, including Abu Dhabi-based MGX and Singapore’s Temasek.
The capital is intended to support the expansion of its AI drug-design platform, research programs and infrastructure.
The funding followed an earlier $600-million external investment announced in March 2025.
Reuters independently reported the May financing as part of a broader industry effort to demonstrate that artificial intelligence can produce meaningful advances in healthcare.
In October, Bloomberg also reported that Isomorphic Labs was in preliminary talks to raise additional funding at a valuation of at least $40 billion, potentially reaching $50 billion.
Those discussions were not a completed financing transaction.
The valuation figure reflects reported negotiations rather than an independently established market price.
Nevertheless, the scale of investor interest demonstrates the commercial expectations surrounding AI-based drug discovery.
Major Pharmaceutical Companies Are Already Working With Isomorphic
Isomorphic Labs is not developing its technology in isolation.
The company has announced research collaborations with major drugmakers, including Novartis, Eli Lilly and Johnson & Johnson.
The partnerships are intended to apply its AI capabilities to pharmaceutical research.
Such agreements may help Isomorphic gain access to scientific expertise and development opportunities while providing established drugmakers with advanced computational capabilities.
But research partnerships do not establish that resulting medicines have received approval.
Each candidate must still progress through appropriate studies.
In the pharmaceutical industry, promising laboratory results frequently fail to translate into successful human treatments.
That uncertainty explains why drugmakers are interested in new technology capable of improving candidate selection.
AI could potentially increase the number of scientifically promising molecules entering development.
The harder challenge is improving the proportion that eventually become safe and effective treatments.
Cancer Research Could Become a Major Testing Ground
Cancer is one of Isomorphic Labs’ principal research priorities.
Developing cancer medicines is especially challenging because different tumors can have distinct molecular characteristics and treatment resistance mechanisms.
Even patients with the same general cancer diagnosis may respond differently to a particular therapy.
AI systems may help researchers analyze complex molecular relationships and identify new targets.
That could eventually support the development of more selective treatments.
However, a molecule that binds to a cancer-related protein may still produce unacceptable side effects or fail to improve patient outcomes.
The gap between promising research and approved medicine remains enormous.
WWC ONE MEDIA previously examined this challenge in Merck and Moderna’s Personalized Cancer Vaccine Shows Major Promise — But a Six-Week Manufacturing Challenge Could Determine How Fast Patients Get It.
That report explored a different technological approach: an experimental personalized mRNA cancer vaccine designed around a patient’s tumor mutations.
The two programs are distinct.
Nevertheless, they demonstrate how pharmaceutical research is increasingly pursuing highly specialized treatments rather than relying exclusively on conventional drug-development approaches.
The Human Clinical Trial Challenge Remains Unsolved
One of Isomorphic Labs’ most important milestones will be moving its internally developed medicines into human trials.
Earlier company statements suggested that initial clinical testing could begin by the end of 2025.
In January 2026, Hassabis said the company was instead targeting the end of 2026.
That represented a delay from the original ambition.
More recent interviews indicate that Isomorphic is strengthening its clinical development capabilities, including building a team in Boston.
However, the company has not publicly confirmed a definitive start date for its first internally developed human trial in the reporting reviewed.
The distinction matters.
Preclinical research evaluates candidate medicines before studies involving patients.
Clinical trials examine safety, dosing, effectiveness and other questions under controlled conditions.
Regulatory agencies require appropriate evidence before authorizing medicines for commercial use.
AI can support that process, but it does not eliminate the need to demonstrate real-world biological effects.
Industry estimates suggest that roughly nine out of ten drug candidates entering clinical development ultimately fail to reach approval, although the percentage varies across therapeutic areas and study definitions.
Reducing that failure rate would represent a major advance.
But Isomorphic has not yet demonstrated that it can eliminate the problem.
Scientific Experts Warn Against Overpromising AI Medicines
Independent reporting from STAT has highlighted the considerable obstacles facing Isomorphic Labs.
The publication interviewed company executives, former employees and outside researchers to evaluate the company’s prospects.
Its findings suggest that Isomorphic has made progress but remains at an early stage of translating its technology into actual medicines.
One major difficulty is that biological systems are extraordinarily complex.
A compound may behave differently inside a living organism than in a computational model.
Researchers must consider how medicines are absorbed, distributed, metabolized and eliminated.
They must also examine potential interactions with biological systems beyond the intended target.
Even accurate predictions about molecular binding cannot answer every question about patient safety or treatment effectiveness.
AI developers are therefore pursuing better models while continuing to depend on experimental validation.
The most meaningful proof of progress will come from successful clinical outcomes, not the number of molecules generated by software.
AI Healthcare Research Is Expanding Beyond Drug Discovery
The pharmaceutical sector is only one area where artificial intelligence is attracting investment.
Healthcare companies are also developing AI systems for diagnostics, medical imaging, clinical documentation and scientific analysis.
WWC ONE MEDIA previously reported on another research effort in Microsoft’s New AI Diagnoses Complex Diseases With 83% Accuracy, Beating Doctors in Tests — But Is It Ready to Treat Real Patients?.
That story described Microsoft’s experimental AI Diagnostic Orchestrator and its performance in controlled diagnostic evaluations.
Diagnostic AI and drug-design AI serve different purposes.
One attempts to help identify medical conditions.
The other seeks to discover or design potential treatments.
But both face a common challenge: strong performance under research conditions does not automatically establish safety and reliability in routine healthcare.
Clinical validation remains essential.
Merck’s Patent Cliff Demonstrates the Need for New Medicines
Major pharmaceutical companies also have commercial reasons to pursue faster drug discovery.
Successful medicines eventually face patent expiration, competing treatments and changing medical needs.
Merck, for example, relies heavily on its blockbuster cancer medicine Keytruda, which faces important US patent-protection changes beginning in 2028.
WWC ONE MEDIA examined the issue in Merck Beats Wall Street With $18.1 Billion in Sales as Keytruda Hits $8.6 Billion — But Can Its Cancer Pipeline Survive the 2028 Patent Cliff?.
The report detailed Merck’s investments in experimental treatments and acquisitions intended to diversify future revenue.
This is one reason AI drug discovery is attracting attention.
If technology can shorten the time required to identify viable candidates, pharmaceutical companies could potentially strengthen their research pipelines.
However, faster discovery does not necessarily mean faster regulatory approval or guaranteed commercial success.
Eli Lilly’s Growth Shows the Financial Stakes
Eli Lilly, one of Isomorphic’s research partners, has become an example of the commercial value of successful medicines.
Its diabetes and obesity treatments have driven substantial revenue growth.
WWC ONE MEDIA examined the company’s latest performance in Eli Lilly Revenue Surges 39% to $24.4 Billion as Mounjaro and Zepbound Smash Records — But Why Did Its Earnings Forecast Fall?.
The drugs discussed in that report are not presented as products developed through Isomorphic’s AI platform.
Instead, Lilly’s financial performance illustrates the potential value of successful pharmaceutical innovation.
A treatment that meets substantial medical needs can become a multibillion-dollar commercial franchise.
But identifying such opportunities early remains difficult.
AI developers hope to improve the efficiency of scientific research, not guarantee that every candidate becomes a successful business.
What Could AI-Designed Medicines Mean for the Philippines?
If AI significantly improves the drug-discovery process, the benefits could eventually extend to patients across Asia, including the Philippines.
More efficient research may lead to additional treatment options for conditions that currently have limited therapies.
Potential applications include cancer, autoimmune diseases and other complex illnesses.
However, faster drug design does not automatically make medicines affordable or available.
Patients still depend on regulatory approvals, pharmaceutical manufacturing, distribution networks, prescribing specialists and healthcare financing.
Prices are influenced by intellectual-property protections, development costs, reimbursement arrangements and market conditions.
For the Philippines, AI-designed medicines would still require appropriate evaluation by health authorities before local commercial use.
A medicine entering clinical trials overseas should not be described as an approved treatment available to Filipino patients.
The promise of the technology is substantial, but its impact on access and affordability remains uncertain.
The Bigger Question: Will AI Design Every Future Medicine?
Isomorphic Labs’ ambition reflects one of the most consequential possible applications of artificial intelligence.
If advanced models can accurately predict molecular behavior and help scientists design better drug candidates, pharmaceutical research could become faster and more efficient.
The company has attracted billions in financing, established relationships with major drugmakers and developed technology extending beyond AlphaFold’s original protein-structure predictions.
But its long-term vision remains unproven.
Human biology is complex.
Clinical trials are demanding.
And regulatory approval requires evidence of safety and effectiveness rather than confidence in computer-generated predictions.
The next milestone will not be another dramatic AI forecast or fundraising announcement.
It will be evidence that an AI-designed treatment works in patients.
As Isomorphic Labs predicts that artificial intelligence will become central to designing every new medicine within five years, can its technology transform promising molecular discoveries into safe, effective treatments — or will the complexity of human biology prove to be the ultimate obstacle?
